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OBJECTIVES The purposes of this study were to describe the prevalence of early recurrences of atrial
fibrillation (ERAF) that occur within two weeks after pulmonary vein (PV) isolation, and to
determine whether ERAF is predictive of long-term outcome after PV isolation.
BACKGROUND Atrial fibrillation (AF) sometimes recurs within days after PV isolation and may prompt an
early repeat intervention.
METHODS Segmental PV isolation was performed using radiofrequency energy in 110 consecutive
patients (mean age 53  11 years) with paroxysmal (93 patients) or persistent (17 patients)
AF. Three to four PVs were targeted for isolation in all patients. Pulmonary vein isolation was
complete in 338 of the 358 PVs that were targeted (94%).
RESULTS Early recurrences of AF occurred in 39 of 110 patients (35%) at a mean of 3.7 3.5 days after
the procedure. The prevalence of ERAF was similar in patients with paroxysmal and
persistent AF (33% and 47%, respectively, p 0.4). Beyond the first two weeks, at 208 125
days of follow-up, 60 of the 71 patients without ERAF (85%) and 12 of the 39 patients with
ERAF (31%) were free of recurrent AF in the absence of antiarrhythmic drug therapy (p 
0.001).
CONCLUSIONS Early recurrences of AF occur in approximately 35% of patients within two weeks after
isolation of three to four PVs, and are associated with a lower long-term success rate than in
patients without ERAF. However, approximately 30% of patients with ERAF have no
further symptomatic AF during long-term follow-up. Therefore, temporary antiarrhythmic
drug therapy may be more appropriate than early repeat ablation in patients with
ERAF. (J Am Coll Cardiol 2002;40:100–4) © 2002 by the American College of
Cardiology Foundation
Isolation of the pulmonary veins (PVs) to eliminate parox-
ysmal or persistent atrial fibrillation (AF) has been per-
formed using a variety of catheter ablation techniques (1–4).
Recurrences of AF after PV isolation have been reported in
up to 40% of patients (1), and may prompt an early repeat
ablation procedure (5). However, the long-term clinical
significance of an early recurrence of atrial fibrillation
(ERAF) after PV isolation has not been well defined. The
purposes of this study were to describe the prevalence of
ERAF within two weeks after PV isolation and to deter-
mine whether ERAF is predictive of long-term outcome.
METHODS
Patient characteristics. Pulmonary vein isolation was per-
formed in 110 consecutive patients with symptomatic par-
oxysmal or persistent AF. The clinical characteristics of
these patients are described in Table 1. For the purposes of
our study, we have defined persistent AF as an episode of
AF that lasted for more than 30 days and required cardio-
version to restore sinus rhythm. All patients were asked to
maintain a log of the episodes of symptomatic AF before
and after the ablation procedure. Seventy of the 110 patients
were included in a prior study that described the clinical
results of PV isolation (4).
PV isolation. All patients provided written informed con-
sent. After trans-septal catheterization, systemic anticoagu-
lation was achieved with intravenous heparin titrated to
maintain an activated clotting time of 250 to 350 s. Selective
venograms of the left superior, left inferior and right
superior PVs were performed. A decapolar catheter with a
distal ring configuration (Lasso Catheter, Biosense Web-
ster, Diamond Bar, California) sequentially was positioned
within 5 mm of the ostium of each PV. A deflectable
quadripolar electrode catheter (EP Technologies, Inc., San
Jose, California) was positioned in the coronary sinus.
Ablation was performed using a deflectable quadripolar 7F
catheter that had 2-5-2 mm interelectrode spacing and a
4-mm distal electrode with an embedded thermistor (EP
Technologies, Inc.). Electrograms were recorded digitally
(EPMed Systems, Inc., Mount Arlington, New Jersey) and
were filtered at bandpass settings of 30 to 500 Hz for bipolar
recordings and 0.05 to 200 Hz for unipolar recordings.
Pulmonary vein isolation was performed by delivering
radiofrequency (RF) energy at a maximum temperature of
52°C and a maximum power of 30 to 35 W for 30 to 60 s
at ostial sites that had the earliest bipolar PV potentials
and/or the most rapid intrinsic deflections in the unipolar
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PV potentials (4,6). Isolation of the left superior, left
inferior and right superior PVs was attempted in all patients.
In 28 patients, isolation of the right inferior PV also was
attempted. Elimination of all PV potentials and entrance
block into the PV were considered indicative of complete
electrical isolation.
Postablation follow-up. After the procedure, all patients
were observed in a telemetry unit for 24 h and were
anticoagulated with warfarin for 6 to 12 weeks. The patients
were seen in an outpatient clinic four to six weeks after the
procedure and three to four months thereafter. No patient
was lost to follow-up.
After the procedure, 39 of the 110 patients (35%) were
treated for one month with a class I (23 patients) or III (16
patients) antiarrhythmic drug. These patients were treated
because of an incomplete isolation of the targeted PVs, a
history of persistent AF or a recurrence of AF during the
24-h observation period after the procedure.
Patients who reported symptoms suggestive of recurrent
AF during follow-up were provided with an event recorder
to document the cause of the symptoms. Any episode of AF
that recurred within two weeks after the PV isolation
procedure was defined as an ERAF. Patients with ERAF
who were not already receiving antiarrhythmic medications
were treated with a class I or III antiarrhythmic drug and/or
a beta-blocker or calcium channel blocker, unless the patient
felt that treatment was not necessary. Antiarrhythmic drug
therapy was discontinued in all patients who had no further
episodes of symptomatic AF after one month.
Statistical analysis. Continuous variables are expressed as
mean  1 SD and were compared using Student t test.
Categorical variables were compared by chi-square analysis.
A Kaplan-Meier analysis was used to determine the prob-
ability of freedom from recurrent AF during follow-up. A
Cox multivariate regression analysis was performed to de-
termine the clinical predictors of ERAF. A value of p 
0.05 was considered significant.
RESULTS
PV isolation. Complete electrical isolation was achieved in
103 of 110 left superior PVs (94%), 104 of 110 right
superior PVs (95%), 103 of 110 left inferior PVs (94%) and
28 of 28 targeted right inferior PVs (100%). Overall, PV
isolation was complete in 338 of the 358 PVs that were
targeted (94%). In 93 of the 110 patients (85%), all targeted
PVs were completely isolated electrically. The mean dura-
tion of RF energy application was 6.4  4.2 min per PV.
Recurrences of AF. During 208  125 days of follow-up,
symptomatic AF recurred in 50 of the 110 patients (45%)
after the ablation procedure. The first recurrent episode
occurred within two weeks of the procedure in 39 of 110
patients (35%), between two weeks and one month after the
procedure in 8 of 110 patients (7%) and between one and
two months after the procedure in 3 of 110 patients (3%)
(Fig. 1).
The mean time to ERAF was 3.7  3.5 days (range 1 to
14 days). Among the 39 patients with ERAF, the first
recurrence of AF occurred within 24 h of the procedure in
33% and within one week of the procedure in 90% (Fig. 2).
Early recurrence of AF occurred in 23 of the 71 patients
(32%) who were discharged from the hospital without
antiarrhythmic drug therapy, and in 16 of the 39 patients
(41%) who were discharged with antiarrhythmic drug ther-
apy after the PV isolation procedure (p  0.4).
Recurrence of AF in patients with paroxysmal and per-
sistent AF. Early recurrence of AF occurred in 31 of 93
patients (33%) with paroxysmal AF and in 8 of 17 patients
(47%) with persistent AF (p  0.3). The mean times to
ERAF were 3.5  3.6 days and 4.6  3.0 days in patients
with paroxysmal and persistent AF, respectively (p  0.4).
At 208  125 days of follow-up, 38 of the 110 patients
(35%) had recurrent episodes of AF beyond the first two
weeks after the PV isolation procedure. Among the 93
patients with paroxysmal AF, 67 (72%) were free from
recurrent episodes of symptomatic AF in the absence of
Abbreviations and Acronyms
AF  atrial fibrillation
ERAF  early recurrence of atrial fibrillation
LVEF  left ventricular ejection fraction
PV  pulmonary vein
RF  radiofrequency
Table 1. Patient Characteristics
Age (yrs) 53  11
Men/women 94 (85)/16 (15)
Paroxysmal AF/persistent AF 93 (85)/17 (15)
Duration of AF (yrs) 7.2  7.7
Episodes of AF (per month) 16  17
LVEF 0.54  0.05
Left atrial size (mm) 41  5
Continuous variables expressed as mean  SD. Percentages shown in parentheses.
AF  atrial fibrillation; LVEF  left ventricular ejection fraction.
Figure 1. Cumulative percent of patients with recurrent atrial fibrillation
(AF) and time to the first recurrence of AF after pulmonary vein isolation
in 110 patients.
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antiarrhythmic drug therapy, compared with only 5 of the
17 patients (30%) with persistent AF (p  0.001).
Frequency of symptomatic episodes of AF before and
after PV isolation. Six of the 39 patients with ERAF
(15%) reported an increase in the frequency of symptomatic
episodes of AF in the first two weeks after the PV isolation
procedure. In these patients, the mean number of episodes
of symptomatic AF was 9  7 in the two weeks before the
ablation procedure, compared with 15 9 in the two weeks
after the ablation procedure (p  0.01). The other 24
patients with ERAF reported either no change in the
frequency of episodes (15 patients), or a decrease from a
mean of 10  7 episodes before the procedure to a mean of
2  1 episode after the procedure (p  0.001).
Time to resolution of ERAF. In patients who had ERAF
but were free from recurrent episodes of AF during long-
term follow-up, the mean time to resolution of symptomatic
episodes of AF was 20  11 days (range 1 to 30 days).
Predictors of ERAF. Among the variables of age, gender,
duration of AF, frequency of AF, presence of structural
heart disease, left ventricular ejection fraction (LVEF), left
atrial size, whether the AF was paroxysmal or persistent,
whether all targeted PVs were completely isolated or not
and total duration of RF energy application, there were no
independent predictors of ERAF.
Long-term outcome in patients with and without ERAF.
During long-term follow-up of the 39 of 110 patients who
had ERAF, 12 (31%) remained free from recurrent episodes
of AF without antiarrhythmic drug therapy. In comparison,
among the 71 patients who did not have ERAF, 60 (85%)
remained free from recurrent episodes of AF without
antiarrhythmic drug therapy (p  0.001) (Fig. 3).
Predictors of long-term freedom from recurrent AF.
Among the variables of age, gender, duration of AF,
presence of structural heart disease, LVEF, left atrial size,
whether AF was paroxysmal or persistent, the number of
completely isolated PVs and ERAF, the absence of ERAF
(p  0.01) and a history of paroxysmal AF (p  0.01) were
the only independent predictors of freedom from recurrent
AF.
Long-term freedom from recurrent AF in patients with
ERAF. Within the group of patients with ERAF, among
the variables of age, gender, presence of structural heart
disease, LVEF, duration of AF, whether the AF was
paroxysmal or persistent, the number of PVs completely
isolated, total duration RF energy application and time to
recurrence of AF, only a history of persistent AF was an
independent predictor of recurrent AF (p  0.05).
DISCUSSION
Main findings. The results of this study demonstrate that
ERAF are common after segmental PV isolation, occurring
in approximately 35% of patients with paroxysmal or per-
sistent AF. Some patients with ERAF experienced a tran-
sient increase in the frequency of episodes of AF. Patients
who had ERAF were significantly less likely to have
long-term freedom from recurrent AF than were patients
without ERAF. Nevertheless, approximately 30% of pa-
tients with ERAF were free from recurrent episodes of
symptomatic AF in the absence of antiarrhythmic drug
therapy during long-term follow-up. There were no clinical
or technique-related predictors of ERAF after PV isolation.
However, a history of persistent AF was an independent
predictor of recurrent episodes of AF among the patients
who had ERAF.
The eventually successful clinical outcome in approxi-
mately one-third of patients with ERAF after PV isolation
suggests that recurrent AF may be a transient phenomenon
and not necessarily an indicator of long-term recurrences of
AF.
Figure 2. Time to the first episode of atrial fibrillation in 39 patients who
had early recurrence of atrial fibrillation (ERAF).
Figure 3. Kaplan-Meier analysis of long-term freedom from recurrent
atrial fibrillation (AF) in patients with and without an early recurrence of
AF (ERAF). PV  pulmonary vein.
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ERAF after PV isolation. Early recurrence of AF was
defined in this study as any recurrence of AF that occurred
within two weeks after the PV isolation procedure. Our
purpose was to identify how often recurrent AF after PV
isolation is a transient phenomenon, caused either by a
delayed therapeutic effect or a transient stimulatory effect of
the RF energy applications. Because acute inflammatory
changes due to RF energy resolve and well-demarcated areas
of necrosis form by two weeks after RF ablation procedures
(7–9), a two-week cutoff for ERAF was used in this study.
Although recurrent episodes of AF that are due to incom-
plete PV isolation, to recovery of conduction in a previously
isolated PV or to arrhythmogenic foci outside the PVs also
may occur within two weeks of PV isolation, these causes of
ERAF would be expected to result in recurrent AF
throughout the follow-up period, not just within the first
two weeks after ablation.
Among the majority of patients in whom recurrent AF
was a transient phenomenon, the mechanism of the tran-
sient AF cannot be defined. However, approximately 15%
of patients who had ERAF in this study had a transient
increase in the frequency of symptomatic episodes of AF
shortly after the PV isolation procedure. In these patients, it
is likely that ERAF was caused by a transient stimulatory
effect of RF energy. It may be that the inflammatory
response that develops after thermal injury transiently ag-
gravates the arrhythmogenic activity of the PVs (10,11).
Several studies have reported an association between inflam-
mation and AF (12–15). Moreover, postoperative AF,
which occurs transiently in 33% of patients after open-
heart surgery, also could be triggered by an inflammatory
response within the atria (16–18).
Among patients who undergo RF catheter ablation of an
accessory pathway and have an unsuccessful acute outcome,
approximately 15% no longer have accessory pathway con-
duction during long-term follow-up (19). A delayed thera-
peutic effect of RF energy may be attributable to growth of
the ablation lesion in the first few days after the procedure
(20). Therefore, it is possible that some patients in this
study no longer had recurrent AF after the first two weeks
of follow-up because of a delayed therapeutic effect of RF
ablation. However, among the majority of patients in this
study in whom recurrent AF was a transient phenomenon,
the mechanism of the transient AF cannot be defined.
Study limitations. A limitation of this study is that recur-
rent episodes of AF after discharge from the hospital were
quantitated on the basis of symptoms reported by the
patients. Although the many episodes of ERAF that oc-
curred within 24 h after ablation and were documented by
continuous telemetric monitoring were always associated
with symptoms, it is possible that asymptomatic episodes of
AF may have been unrecognized after discharge from the
hospital. However, all patients had symptomatic AF before
the ablation procedure, and symptomatic episodes of AF
were confirmed with an event recorder.
Clinical implications. In conclusion, in approximately
30% of patients who experience recurrent episodes of AF
within two weeks after segmental ostial ablation to isolate
the PVs, the AF may be a transient phenomenon that
eventually resolves and may be caused by acute stimulatory
effects of RF energy or may be a delayed therapeutic effect
of RF ablation. In some centers, patients are monitored for
several days after PV isolation, and an early repeat ablation
is attempted if ERAF occurs (5). However, because AF
often does not recur long-term in patients who have had
ERAF, a brief course of antiarrhythmic drug therapy may be
more appropriate than an early repeat ablation procedure.
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